摘要
分子靶向治疗成为结直肠癌治疗的新突破,其中包括抗表皮生长因子受体(EGFR)单克隆抗体。如何寻找使用抗EGFR单抗的优势人群,从而避免不必要的毒副作用和无效治疗是目前研究的热点。本文就目前国内外研究较多的预测抗EGFR单抗疗效的生物靶标作一综述。
Molecular targeted therapy has been a promising treatment for colorectal cancer today,which includes anti-EGFR（epithelial growth factor receptor） monoclonal antibody.How to select beneficial patients for this therapy,so as to avoid unnecessary toxicity and invalid expense,is a hotspot of research.The object of the review is to introduce some biomarkers which may predict efficacy of the anti-EGFR monoclonal antibody therapy.
出处
《临床肿瘤学杂志》
CAS
2010年第5期457-460,共4页
Chinese Clinical Oncology
关键词
分子靶向治疗
抗EGFR单抗
生物靶标
Molecular targeted therapy
Anti-EGFR monoclonal antibody
Biomarker
